Literature DB >> 28395201

Syndecan-4 deficiency accelerates the transition from compensated hypertrophy to heart failure following pressure overload.

Guannan Li1, Jun Xie1, Jianzhou Chen1, Ran Li1, Han Wu1, Xinlin Zhang1, Qinhua Chen1, Rong Gu2, Biao Xu3.   

Abstract

Increasing evidence suggests that a mismatch between angiogenesis and myocardial growth contributes to the transition from adaptive cardiac hypertrophy to heart failure following pressure overload. Syndecan-4 is a transmembrane proteoglycan that binds to growth factors and extracellular matrix proteins and is critical in focal adhesion formation. However, its effects on coronary angiogenesis during pressure overload-induced heart failure have not been studied. Here, we hypothesize that syndecan-4 modulates cardiac remodeling in response to pressure overload through its ability to regulate adaptive angiogenesis. Syndecan-4 knockout (syndecan-4 KO) and wild-type (WT) mice were subjected to pressure overload induced by transverse aortic constriction (TAC). Syndecan-4 KO mice exhibited reduced capillary density, attenuated cardiomyocyte size, and worsened left ventricular cardiac function after TAC surgery compared with WT mice. Moreover, syndecan-4 KO mice showed a significant decrease in protein kinase C alpha expression. Our data suggest that syndecan-4 is essential for the compensated hypertrophy and the maintenance of cardiac function during the process of heart failure following pressure overload.
Copyright © 2017. Published by Elsevier Inc.

Entities:  

Keywords:  Angiogenesis; Cardiac hypertrophy; Heart failure; PKCα; Syndecan-4

Mesh:

Substances:

Year:  2017        PMID: 28395201     DOI: 10.1016/j.carpath.2017.03.008

Source DB:  PubMed          Journal:  Cardiovasc Pathol        ISSN: 1054-8807            Impact factor:   2.185


  7 in total

1.  GDF11 Decreases Pressure Overload-Induced Hypertrophy, but Can Cause Severe Cachexia and Premature Death.

Authors:  Shavonn C Harper; Jaslyn Johnson; Giulia Borghetti; Huaqing Zhao; Tao Wang; Markus Wallner; Hajime Kubo; Eric A Feldsott; Yijun Yang; Yunichel Joo; Xinji Gou; Abdel Karim Sabri; Priyanka Gupta; Maria Myzithras; Ashraf Khalil; Michael Franti; Steven R Houser
Journal:  Circ Res       Date:  2018-11-09       Impact factor: 17.367

2.  Cardiomyocyte-specific overexpression of syndecan-4 in mice results in activation of calcineurin-NFAT signalling and exacerbated cardiac hypertrophy.

Authors:  Ida G Lunde; J Magnus Aronsen; A Olav Melleby; Mari E Strand; Jonas Skogestad; Bård A Bendiksen; M Shakil Ahmed; Ivar Sjaastad; Håvard Attramadal; Cathrine R Carlson; Geir Christensen
Journal:  Mol Biol Rep       Date:  2022-10-07       Impact factor: 2.742

Review 3.  Biomarkers of Myocardial Injury and Remodeling in Heart Failure.

Authors:  Barbara Ponikowska; Gracjan Iwanek; Agata Zdanowicz; Szymon Urban; Robert Zymliński; Piotr Ponikowski; Jan Biegus
Journal:  J Pers Med       Date:  2022-05-16

4.  Syndecan-4 Inhibits the Development of Pulmonary Fibrosis by Attenuating TGF-β Signaling.

Authors:  Yoshinori Tanino; Xintao Wang; Takefumi Nikaido; Kenichi Misa; Yuki Sato; Ryuichi Togawa; Takaya Kawamata; Masami Kikuchi; Charles W Frevert; Mishie Tanino; Tetsuhito Kojima; Yoko Shibata
Journal:  Int J Mol Sci       Date:  2019-10-09       Impact factor: 5.923

5.  The female syndecan-4-/- heart has smaller cardiomyocytes, augmented insulin/pSer473-Akt/pSer9-GSK-3β signaling, and lowered SCOP, pThr308-Akt/Akt and GLUT4 levels.

Authors:  Thea Parsberg Støle; Marianne Lunde; Xin Shen; Marita Martinsen; Per Kristian Lunde; Jia Li; Francesca Lockwood; Ivar Sjaastad; William Edward Louch; Jan Magnus Aronsen; Geir Christensen; Cathrine Rein Carlson
Journal:  Front Cell Dev Biol       Date:  2022-08-25

6.  Syndecan-4 is More Sensitive in Detecting Hypertensive Left Ventricular Diastolic Dysfunction in 2K2C Rats.

Authors:  Wenyue Dai; Yanqiu Liu; Fengjuan Yao; Wei Li; Jia Liu; Cuiling Li; Donghong Liu
Journal:  Int J Hypertens       Date:  2022-09-24       Impact factor: 2.434

Review 7.  Syndecan receptors: pericellular regulators in development and inflammatory disease.

Authors:  Sandeep Gopal; Samantha Arokiasamy; Csilla Pataki; James R Whiteford; John R Couchman
Journal:  Open Biol       Date:  2021-02-10       Impact factor: 6.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.